Experts question Alzheimer's treatment strategy after Biogen failure

Though some Massachusetts startups and researchers are maintaining a dogged determinedness in targeting a protein called amyloid beta, many are calling Biogen's aducanumab failure the last nail in the coffin.

Source: bizjournals.com Health Care:Physician Practices headlines - March 22, 2019 Category: American Health Authors: Allison DeAngelis Source Type: news